Share of global biopharmaceutical pipeline vs First-in-class drug approvals in China
In 2025, share of global biopharmaceutical pipeline in China was 30%; first-in-class drug approvals was 11.
Change the pair
Compare different indicators
The series
Over time
China, spaced by time in 2025 . Different units, drawn on separate scales and clipped to the years both series publish — earlier history stays on each indicator's own page. Read the values, not the heights.
Share of global biopharmaceutical pipeline
Unit: % · 1 observation
View the underlying data
| Period | Type | Value |
|---|---|---|
| 2025 | Actual | 30% |
First-in-class drug approvals
Unit: count · 1 observation
View the underlying data
| Period | Type | Value |
|---|---|---|
| 2025 | Actual | 11 |
Shared periods
Side by side
Only one period is published for both series in China. Comparing anything else would mean comparing different years.
Provenance
Where these numbers come from
Share of global biopharmaceutical pipeline
Proportion of global biopharmaceutical research and development pipeline assets originating from a specific country or region.
2 observations in China · source organisations: State Council
First-in-class drug approvals
Number of approved therapeutic drugs featuring a novel biological mechanism of action.
4 observations in China · source organisations: NMPA, NHSA
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring